[ad_1] Korea BMS Pharmaceuticals and Pfizer Korea announced that an oral anticoagulant Elyquis has been approved for use in remedies for the treatment of critically ill patients with atrial fibrillation requiring conversion …
Read More »Atrial fibrillation The leading cause of stroke in Koreans is "age"
[ad_1] It is more important than companion disease, and it should be changed according to the criteria of the Korean index. The badysis of the risk factor of stroke in Korean patients …
Read More »[약업신문] Targeting High Risk Atrial Fibrillation & # 39; … NOAC competing on a large scale
[ad_1] The oral anticoagulant without vitamin K antagonist (NOAC), an oral anticoagulant without vitamin K, competes to gain dominance in high risk groups of atrial fibrillation. In fact, none of the NOACs …
Read More »